RT Journal Article
T1 Pleiotrophin-Loaded Mesoporous Silica Nanoparticles as aPossible Treatment for Osteoporosis
A1 Lozano Borregón, Daniel
A1 Leiva, Beatriz
A1 Gómez-Escalonilla, Inés
A1 Portal Núñez, Sergio
A1 Gortázar, Arancha R.
A1 Manzano García, Miguel
A1 Vallet Regí, María Dulce Nombre
AB Osteoporosis is the most common type of bone disease. Conventional treatments are based on the use of antiresorptive drugs and/or anabolic agents. However, these treatments have certain limitations, such as a lack of bioavailability or toxicity in non-specific tissues. In this regard, pleiotrophin (PTN) is a protein with potent mitogenic, angiogenic, and chemotactic activity, with implications in tissue repair. On the other hand, mesoporous silica nanoparticles (MSNs) have proven to be an effective inorganic drug-delivery system for biomedical applications. In addition, the surface anchoring of cationic polymers, such as polyethylenimine (PEI), allows for greater cell internalization, increasing treatment efficacy. In order to load and release the PTN to improve its effectiveness, MSNs were successfully internalized in MC3T3-E1 mouse pre-osteoblastic cells and human mesenchymal stem cells. PTN-loaded MSNs significantly increased the viability, mineralization, and gene expression of alkaline phosphatase and Runx2 in comparison with the PTN alone in both cell lines, evidencing its positive effect on osteogenesis and osteoblast differentiation. This proof of concept demonstrates that MSN can take up and release PTN, developing a potent osteogenic and differentiating action in vitro in the absence of an osteogenic differentiation-promoting medium, presenting itself as a possible treatment to improve bone-regeneration and osteoporosis scenarios.
PB MDPI
SN 1999-4923
YR 2023
FD 2023-02-16
LK https://hdl.handle.net/20.500.14352/73414
UL https://hdl.handle.net/20.500.14352/73414
LA eng
NO Universidad CEU San Pablo
NO European Research Council
NO Ministerio de Ciencia e Innovación
DS Docta Complutense
RD 6 abr 2025